Case reports in neurology · 2026
Weight Drop-Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-Mediated Weight Loss.
Название и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tanyous AI, Levitt JO
Аннотация
INTRODUCTION: Common peroneal nerve palsy, termed "slimmer's palsy," is a recognized complication of rapid weight loss. This case series describes 2 patients who developed foot drop following tirzepatide-induced weight loss precipitated by habitual leg crossing.
CASE PRESENTATIONS: Peroneal neuropathy secondary to compression from habitual leg crossing developed in 2 male patients during tirzepatide therapy for weight loss. Patient 1 was a 55-year-old with severe hidradenitis suppurativa on multiple immunosuppressive medications who started on tirzepatide and lost 50 pounds over 5 months. Patient 2 was a 71-year-old with insulin resistance who lost 30 pounds over 3 months on tirzepatide. Both patients developed foot drop over 24-72 h. Treatment was behavioral modification to avoid leg crossing, supplemented by physical therapy, and, in patient 1, ankle bracing. Foot drop signs resolved over 3 to 4 months.
CONCLUSION: Clinicians prescribing tirzepatide should counsel patients about peroneal nerve palsy risk during rapid weight loss. Patients should avoid prolonged leg crossing. Early recognition enables timely intervention and favorable outcomes.
CASE PRESENTATIONS: Peroneal neuropathy secondary to compression from habitual leg crossing developed in 2 male patients during tirzepatide therapy for weight loss. Patient 1 was a 55-year-old with severe hidradenitis suppurativa on multiple immunosuppressive medications who started on tirzepatide and lost 50 pounds over 5 months. Patient 2 was a 71-year-old with insulin resistance who lost 30 pounds over 3 months on tirzepatide. Both patients developed foot drop over 24-72 h. Treatment was behavioral modification to avoid leg crossing, supplemented by physical therapy, and, in patient 1, ankle bracing. Foot drop signs resolved over 3 to 4 months.
CONCLUSION: Clinicians prescribing tirzepatide should counsel patients about peroneal nerve palsy risk during rapid weight loss. Patients should avoid prolonged leg crossing. Early recognition enables timely intervention and favorable outcomes.